RxDoctor Payments Data

Bassam Habbal, MD

Interventional Cardiology · Oak Lawn, ILNPI 1427041243

Payments from drug & device makers

$3,282in general payments, 2019–2025

Across 192 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$680
  • Esperion Therapeutics, Inc.$403
  • E.r. Squibb & Sons, L.L.C.$336
  • Johnson & Johnson$330
  • Medtronic$318
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$250
  • plus $963 from 13 others

What the payments were for

  • Food & beverage$3,18597%
  • Education$963%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,282 in reported general payments places this provider in the 25th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$284,020
Medicare patients
646
Services billed
2,863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban536$536,899
EntrestoSacubitril/Valsartan84$88,964
XareltoRivaroxaban71$78,863
MultaqDronedarone Hcl58$74,179
JardianceEmpagliflozin55$62,532
FarxigaDapagliflozin Propanediol49$43,497
Repatha SureclickEvolocumab52$32,841
BrilintaTicagrelor36$24,136
VascepaIcosapent Ethyl38$15,779
NexlizetBempedoic Acid/Ezetimibe18$14,248
Ranolazine ErRanolazine80$11,075
Metoprolol Succinate619$9,829
Atorvastatin Calcium577$6,703
Ezetimibe240$6,196
Icosapent Ethyl24$5,659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$165$536,899536 claims
NovartisEntresto$680$88,96484 claims
Johnson & JohnsonXarelto$330$78,86371 claims
Sanofi-aventis U.S. LLCMultaq$94$74,17958 claims
AstraZenecaFarxiga, Brilinta$186$67,63385 claims
Boehringer IngelheimJardiance$67$62,53255 claims
Esperion Therapeutics, Inc.Nexlizet$403$14,24818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Oak Lawn

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →